Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Research & Development (2020 - 2025)

Maxcyte (MXCT) has disclosed Research & Development for 6 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 27.72% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.8 million through Dec 2025, down 6.32% year-over-year, with the annual reading at $20.8 million for FY2025, 6.32% down from the prior year.
  • Research & Development for Q4 2025 was $3.3 million at Maxcyte, down from $5.3 million in the prior quarter.
  • The five-year high for Research & Development was $6.7 million in Q1 2024, with the low at $2.7 million in Q3 2021.
  • Average Research & Development over 5 years is $5.1 million, with a median of $5.5 million recorded in 2022.
  • The sharpest move saw Research & Development crashed 39.2% in 2021, then skyrocketed 93.86% in 2022.
  • Over 5 years, Research & Development stood at $3.4 million in 2021, then surged by 69.45% to $5.7 million in 2022, then increased by 2.0% to $5.8 million in 2023, then dropped by 21.02% to $4.6 million in 2024, then decreased by 27.72% to $3.3 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $3.3 million, $5.3 million, and $6.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.